FIRST TRACKS BIOTHERAPEUTICS INC (TRAX) competitors & alternatives
Health Care · NASDAQ
FIRST TRACKS BIOTHERAPEUTICS INC (TRAX)'s top competitors and alternatives — its most similar public companies — include ANAPTYSBIO INC (ANAB), APOGEE THERAPEUTICS INC (APGE), JADE BIOSCIENCES INC (JBIO), ABSCI CORP (ABSI), DAMORA THERAPEUTICS INC (DMRA), SPYRE THERAPEUTICS INC (SYRE), ORUKA THERAPEUTICS INC (ORKA), FORTE BIOSCIENCES INC (FBRX), XENCOR INC (XNCR), Roivant Sciences (ROIV), ZURA BIO LTD CLASS A (ZURA) and AVALO THERAPEUTICS INC (AVTX). These are FIRST TRACKS BIOTHERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top TRAX competitors & alternatives
-
ANAPTYSBIO INCANABHealth Care
AnaptysBio is an immunotherapy company generating revenue from blockbuster royalties (Jemperli with GSK, imsidolimab with Vanda) while pursuing its own…
$52.61 (as of 2026-07-22) · market cap $1.6B
-
APOGEE THERAPEUTICS INCAPGEHealth Care
Apogee is a clinical-stage biotech developing optimized, extended half-life monoclonal antibodies targeting IL-13, IL-4 receptor alpha, and other inflammatory…
$134.08 (as of 2026-07-22) · market cap $10.1B
-
JADE BIOSCIENCES INCJBIOHealth Care
Jade Biosciences is a clinical-stage biotech developing next-generation monoclonal antibodies with extended half-lives to treat autoimmune diseases like IgA…
$19.85 (as of 2026-07-22) · market cap $1.2B
-
ABSCI CORPABSIHealth Care
Absci is a clinical-stage drug developer leveraging a generative AI platform to rapidly design and validate novel, differentiated antibody therapeutics for…
$8.24 (as of 2026-07-22) · market cap $1.4B
-
DAMORA THERAPEUTICS INCDMRAHealth Care
Damora Therapeutics is a biotechnology company developing a pipeline of precision antibody therapies specifically targeting mutCALR-driven myeloproliferative…
$29.99 (as of 2026-07-22) · market cap $1.8B
-
SPYRE THERAPEUTICS INCSYREHealth Care
Spyre is developing a portfolio of long-acting engineered antibodies and combinations targeting validated inflammatory pathways in IBD and rheumatic diseases…
$99.17 (as of 2026-07-22) · market cap $8.6B
-
ORUKA THERAPEUTICS INCORKAHealth Care
Clinical-stage biopharmaceutical company developing novel monoclonal antibodies with extended half-life for inflammatory and immunology indications, led by…
$92.53 (as of 2026-07-22) · market cap $5.6B
-
FORTE BIOSCIENCES INCFBRXHealth Care
A clinical-stage biotech developing an anti-CD122 antibody (FB102) to modulate immune cells in autoimmune diseases, with promising early celiac disease data…
$56.63 (as of 2026-07-22) · market cap $1.2B
-
XENCOR INCXNCRHealth Care
Xencor is a clinical-stage biopharmaceutical company leveraging its proprietary XmAb antibody engineering platform to develop innovative multi-specific…
$19.51 (as of 2026-07-22) · market cap $1.4B
-
Roivant SciencesROIVHealth Care
Roivant Sciences is a biopharma-tech incubator that uses a 'Vant' subsidiary model and computational discovery tools to accelerate the development of…
$34.91 (as of 2026-07-22) · market cap $25.1B
-
ZURA BIO LTD CLASS AZURAHealth Care
Zura Bio is developing differentiated bispecific and monoclonal antibodies targeting immune pathways in autoimmune and inflammatory diseases where current…
$5.40 (as of 2026-07-22) · market cap $532M
-
AVALO THERAPEUTICS INCAVTXHealth Care
Clinical-stage biotech developing abdakibart, a humanized anti-IL-1β antibody for hidradenitis suppurativa with Phase 2 data readout expected mid-2026.
$18.15 (as of 2026-07-22) · market cap $961M
Not quite? Describe exactly what you want →
Peers are FIRST TRACKS BIOTHERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: FIRST TRACKS BIOTHERAPEUTICS INC (TRAX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.